Advertisement

Header Utility Menu

  • Subscribe
  • Advertise
  • Contact Us
  • Events

LinkedIn Facebook Twitter Instagram Get Our App

  • Login

Virginia Business

Mobile Menu

  • Issues
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • Nominate a Virginia financial professional
    • Nominate A Woman in Leadership Today
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Advertisement

Header Primary Menu

  • Issues
    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • Issues Archive
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • Nominate a Virginia financial professional
    • Nominate A Woman in Leadership Today
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Home News Industries Healthcare VCU scientists studying cancer drug as COVID-19 treatment

VCU scientists studying cancer drug as COVID-19 treatment

AR-12 medication prevents coronavirus from replicating in cells

Published September 21, 2020 by Kate Andrews

A group of scientists at Virginia Commonwealth University’s Massey Cancer Center discovered that an experimental cancer drug keeps the virus that causes COVID-19 from infecting cells and replicating. Their findings were published Monday in the Biochemical Pharmacology journal and will be tested in a clinical trial at VCU Health.

AR-12 has been studied as an anti-cancer and antiviral drug in Massey researcher Paul Dent’s lab, and Dent and others have found that the oral medication is effective against Zika, mumps, measles, drug-resistant HIV and the flu, according to a news release from VCU. Laurence Booth of VCU and Jonathan O. Rayner of the University of South Alabama have studied the drug’s use in treating patients with COVID-19. They found it is “highly effective” against SARS-CoV-2, the virus that causes COVID.

Dent’s team also found that people of non-European descent, particularly those of African ancestry, make one type of protein, while people of European descent make a variant. This difference may explain why African American people are more prone to serious cases of COVID-19, although Dent cautioned that the observation is not conclusive. “It provides a biomarker that could be evaluated to help explain why some people get more severe illness than others,” he said in a statement.

“AR-12 works in a unique way,” added Dent, the chair of Massey’s Cancer Cell Signaling research program and a professor at VCU’s biochemistry and molecular biology department. “Unlike any other antiviral drug, it inhibits cellular chaperones, which are proteins that are required to maintain the right 3D shape of viral proteins. The shape of the virus is critical to its ability to infect and replicate.”

Dr. Andrew Poklepovic, a medical oncologist and medical director of Massey’s Clinical Trials Office, is leading the effort to start a clinical trial. In prior trials for other diseases, the medication was “safe and tolerable” to patients, Poklepovic said in a statement. Unlike most other COVID-19 drugs, which are given intravenously, AR-12 is taken orally and could be used for outpatient therapy, he said.

The Food and Drug Administration must give its approval to test the drug on COVID patients, and VCU is in talks with a drug company to manufacture enough of the medication for the trial. C19 Therapeutics, a group of entrepreneurs gathered by Massey’s associate director for basic research, Said Sebti, has recently licensed AR-12 from VCU to raise funds in support of clinical trial sponsorship.

“We are working to submit the required information for FDA approvals, and we are also in discussions with a local pharmaceutical company to manufacture the drug for the trial,” Sebti said in a statement. “We are hopeful that AR-12 will emerge as a treatment option for patients suffering from COVID-19, ultimately saving lives and contributing to the global pandemic solution.”

Other potential treatments for COVID-19 have gotten accelerated approval for testing on humans through the Coronavirus Treatment Acceleration Program.

 

Subscribe to Virginia Business.

Get our daily e-newsletter.

Related Stories

Dr. Eric Edwards

Trump administration chooses RVA pharma startup for $354M COVID-19 contract

Phlow Corp. will create domestic supply chain for coronavirus drugs

Virginia Business logo

Two long-term care facility residents in Henrico die from virus; Va. toll at 9

Canterbury Rehabilitation and Healthcare Center had four positive cases last week

Virginia Business logo

U.S. employment rising slightly but still mostly flat, survey says

More COVID-19 cases recently have likely created economic uncertainty.

Trending

ESPN: Snyders receive two $6B bids for Commanders

Youngkin announces $8.1M in GO Virginia grants

Capital Square launches subsidiary to oversee multifamily portfolio

ITA International names new CEO

Arko tries to keep $1.4B TravelCenters of America bid alive

Sponsored Stories

Working at Pinnacle Financial Partners

What Logistics issues will have the biggest impact on you in 2023?

In the New Year, Aim for Better Cybersecurity

Advertisement

Advertisement

Trending

ESPN: Snyders receive two $6B bids for Commanders

Youngkin announces $8.1M in GO Virginia grants

Capital Square launches subsidiary to oversee multifamily portfolio

ITA International names new CEO

Arko tries to keep $1.4B TravelCenters of America bid alive

Sponsored Stories

Working at Pinnacle Financial Partners

What Logistics issues will have the biggest impact on you in 2023?

In the New Year, Aim for Better Cybersecurity

Get Virginia Business directly on your tablet or in your mailbox!

Subscribe to Virginia Business

Advertisement

Advertisement

Footer Primary Menu

  • virginiabusiness.com
  • Subscribe
  • Advertise
  • About Us
  • Contact Us

Footer Secondary Menu

  • Industries
  • Regions
  • Reports
  • Company News
  • Events

Sign Up For Our Newsletter

Sign Up

LinkedIn Facebook Twitter Instagram Get Our App

Privacy Policy Cookie Policy

Footer Utility Menu

Copyright © 2023 Virginia Business. All rights reserved.

Site Maintained by TechArk